Website
N/ATelephone
61.8.9389.1992
Address
QQ Block, Nedlands 6 Verdun Street QEII Medical Centre Perth, Western Australia (WA) 6009
Description
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.28 - 1.12
Trade Value (12mth)
AU$34,604.00
1 week
5.88%
1 month
13.92%
YTD
-42.68%
1 year
-55.88%
All time high
1.48
EPS 3 yr Growth
80.40%
EBITDA Margin
-916.60%
Operating Cashflow
-$6m
Free Cash Flow Return
-62.00%
ROIC
-70.70%
Interest Coverage
-352.80
Quick Ratio
10.10
Shares on Issue (Fully Dilluted)
131m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.33
Date | Announcements |
---|---|
08 July 25 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
07 July 25 |
Notification of cessation of securities - PIQ
×
Notification of cessation of securities - PIQ |
04 July 25 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
04 July 25 |
Top 20 Holders and Range of Units for Attaching Options
×
Top 20 Holders and Range of Units for Attaching Options |
03 July 25 |
AMA grants reimbursement code for Next-Gen PromarkerD test
×
AMA grants reimbursement code for Next-Gen PromarkerD test |
01 July 25 |
Funding boost for precision diagnostics Proteomics Facility
×
Funding boost for precision diagnostics Proteomics Facility |
30 June 25 |
First patent for endometriosis blood test - granted in Japan
×
First patent for endometriosis blood test - granted in Japan |
23 June 25 |
Next-gen PromarkerD test system released for predicting DKD
×
Next-gen PromarkerD test system released for predicting DKD |
20 June 25 |
PromarkerD launched into the US at major diabetes conference
×
PromarkerD launched into the US at major diabetes conference |
13 June 25 |
Change of Director's Interest Notices x 4
×
Change of Director's Interest Notices x 4 |
10 June 25 |
Notice Under Section 708A
×
Notice Under Section 708A |
06 June 25 |
Supplementary Prospectus
×
Supplementary Prospectus |
06 June 25 |
Update - Proposed issue of securities - PIQ
×
Update - Proposed issue of securities - PIQ |
06 June 25 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
06 June 25 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
06 June 25 |
Notification regarding unquoted securities - PIQ
×
Notification regarding unquoted securities - PIQ |
06 June 25 |
Notification regarding unquoted securities - PIQ
×
Notification regarding unquoted securities - PIQ |
06 June 25 |
Notification regarding unquoted securities - PIQ
×
Notification regarding unquoted securities - PIQ |
05 June 25 |
$12 million capital raise completed with oversubscribed SPP
×
$12 million capital raise completed with oversubscribed SPP |
05 June 25 |
A landmark in non-invasive Esophageal Cancer diagnosis
×
A landmark in non-invasive Esophageal Cancer diagnosis |
30 May 25 |
Results of Meeting
×
Results of Meeting |
26 May 25 |
PromarkerEndo latest results presented at world congress
×
PromarkerEndo latest results presented at world congress |
15 May 25 |
Chinese patent granted for OxiDx technology
×
Chinese patent granted for OxiDx technology |
05 May 25 |
Share Purchase Plan Offer Booklet
×
Share Purchase Plan Offer Booklet |
02 May 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.